About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair® (omalizumab)

Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has validated and accepted the marketing authorization application (MAA) for ADL-018, the Company’s proposed biosimilar for Xolair® (omalizumab). The acceptance marks a critical milestone in our commitment to developing cost-effective therapies to patients with moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic spontaneous urticaria.

The MAA is supported by a comprehensive data package, including extensive analytical, preclinical, pharmacokinetic, pharmacodynamic, safety, and immunogenicity studies demonstrating that ADL-018 is highly similar to the reference product, Xolair®, in terms of quality, safety, and efficacy.

"The MHRA’s acceptance of the MAA for ADL-018 brings us one step closer to offering patients in the UK a cost-effective alternative to Xolair®," said Chirag and Chintu Patel, Executive Chairman and Co-Founders of Kashiv Biosciences. "This acknowledgement by the MHRA underscores our dedication to expanding access to vital biologic therapies and addressing unmet medical needs."

“This represents an important step in the development of our proposed biosimilar to Xolair, with the key goal to increase patient access to an important biologic,” said Joseph McClellan, Chief Scientific Officer of Alvotech.

“We are pleased to see the MHRA’s acceptance of the MAA for ADL-018, which reflects the strength of our scientific collaboration and the shared vision to increase access to high-quality, affordable biologics,” said Dr. Nick Warwick, Chief Medical Officer at ADVANZ PHARMA. “This is a significant step forward in our mission to bringing biosimilar medicines to more patients across the UK and beyond.”

Kashiv Biosciences has a robust pipeline of biosimilar products, reflecting their deep commitment to delivering high-quality therapeutic options. The acceptance for ADL-018 aligns with the Company’s strategic goal to broaden the portfolio on a global scale.

About Kashiv:

Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines.

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has validated and accepted the marketing authorization application (MAA) for ADL-018, the Company’s proposed biosimilar for Xolair® (omalizumab)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.